Multiple Myeloma Connect
  • Saved

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma - PubMed

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34046363/

Belantamab mafodotin (belamaf), an antibody-drug conjugate approved for the treatment of relapsed and refractory multiple myeloma (RRMM), is an anti B-cell maturation antigen (BCMA) agent. DREAMM-1, a first in-human trial...

  • Saved

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Source : https://onlinelibrary.wiley.com/doi/10.1111/bjh.17541

Bortezomib- and lenalidomide-based therapies have become standard front-line treatment for multiple myeloma (MM),1 resulting in many patients being refractory to bortezomib or lenalidomide at first relapse.2, 3 This may negatively...

  • Saved

Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma - PubMed

Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34014671/

Multiple myeloma is an incurable hematological malignancy that impacts tens of thousands of people every year in the United States. Treatment for eligible patients involves induction, consolidation with stem cell...

  • Saved

Accidental Ixazomib Overdose in a Patient With Multiple Myeloma - PubMed

Accidental Ixazomib Overdose in a Patient With Multiple Myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33980053/

Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received...

  • 5yr
    Valuable piece as our best intended instructions don’t always “reach” the patient and while hopefully uncommon, this can be a resource for a practicing clinician
  • 5yr
    Please share your thoughts concerning overdose on oral chemotherapy.

Show More Comments

  • Saved

The Proximal Tubule Toxicity of Immunoglobulin Light Chains - PubMed

The Proximal Tubule Toxicity of Immunoglobulin Light Chains - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34013100/

Plasma and B cells dyscrasias that overproduce monoclonal immunoglobulin free light chains (FLCs) affect the kidney frequently in various ways. The hematologic dyscrasia responsible for the production of FLCs may...